Demethylase FTO significantly promoted melanoma tumorigenesis and decreased response to anti-PD-1 blockade immunotherapy, suggesting that FTO inhibition combined with anti-PD-1 blockade may sensitize immunotherapy in melanoma (14). This evidence concerns the gene MBD2 and melanoma.